Personalis Inc.

02/17/2026 | Press release | Distributed by Public on 02/17/2026 15:05

Personalis to Participate in the TD Cowen 46th Annual Healthcare Conference

FREMONT, Calif.--(BUSINESS WIRE)--Feb. 17, 2026-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the TD Cowen 46th Annual Healthcare Conference on Tuesday, March 3, 2026 at the Boston Marriott Copley Place in Boston, MA.

About Personalis, Inc.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care throughout the patient journey. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in Fremont, California. To learn more, visit www.personalis.com and connect with us on LinkedIn and X (Twitter).

View source version on businesswire.com: https://www.businesswire.com/news/home/20260217655785/en/

Investor Relations:
Caroline Corner
[email protected]
415-202-5678

Media:
[email protected]

Source: Personalis, Inc.

Personalis Inc. published this content on February 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on February 17, 2026 at 21:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]